-
1.发明公开
公开(公告)号：EP3699199A2
公开(公告)日：2020-08-26
申请号：EP18868854.3
申请日：2018-10-22
发明人： KIM, Ki Su , JEONG, Jun Hong , KIM, Dong Sik , LIM, Yang Mi , PARK, Yong Yea , LIM, Hyung Kwon , WON, Jong Wha
IPC分类号： C07K16/30
摘要： The present invention relates to an anti-MSLN antibody and a pharmaceutical composition for cancer treatment comprising same. The anti-MSLN antibody according to the present invention has high affinity and specificity for MSLN and thus can be effectively used in cancer prevention or treatment.
-
公开(公告)号：EP3601361A1
公开(公告)日：2020-02-05
申请号：EP18772021.4
申请日：2018-03-23
发明人： EUN, So-Young , OH, Miyoung , PARK, Hye-Young , LEE, Mijung , YOON, Aerin , YUM, Hye In , NAM, Hyemi , LEE, Eunhee , WON, Jongwha
IPC分类号： C07K16/28 , A61K39/395 , A61K35/17 , A61K39/39 , A61K39/00
-
公开(公告)号：EP2832363B1
公开(公告)日：2018-09-19
申请号：EP13769431.1
申请日：2013-03-27
发明人： KIM, Se-Ho , HONG, Kwang-Won , CHANG, Ki Hwan , KIM, Min-Soo , LEE, Mi-Jung , WON, Jong-Hwa , HUR, Min-Kyu , CHO, Hyun-soo , YOO, Ji-Ho
CPC分类号： C07K16/3046 , A61K39/0005 , A61K39/0011 , A61K2039/53 , C07K16/2863 , C07K2317/10 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/567 , C07K2317/76 , C12N15/1037 , G01N33/57492 , G01N2333/71
摘要： The present invention relates to epitopes of the epidermal growth factor receptor (EGFR) and the use thereof. The epitopes provided by the present invention are highly preserved, and located in the domain closely related to binding with an epidermal growth factor (EGF). Therefore, vaccine compositions comprising the epitopes or compositions comprising antibodies to the epitopes may efficiently block a signal transduction caused by binding of EGF and EGRF, and thus can be highly valuably used in treating various diseases such as cancer. An antibody bound to the epitopes of the present invention may efficiently inhibit binding of various EGFR ligands such as not only EGF but also TGF-a, AR, BTC, EPR and HB-EGF, with EGFR, and therefore can be used in treating various diseases resulting from an activation of EGFR caused by binding not only with EGF but also with other EGFR ligands.
-
公开(公告)号：EP3247394A2
公开(公告)日：2017-11-29
申请号：EP16740356.7
申请日：2016-01-15
发明人： CHOI, Yong Woon , KIM, Yoo Hoon , CHOI, Jungsub
IPC分类号： A61K39/395 , A61K47/34
CPC分类号： A61K39/39591 , A61K39/3955 , A61K39/39558 , A61K47/10 , A61K47/12 , A61K47/183 , A61K47/26 , C07K16/2863 , C07K2317/94
摘要： The present invention provides a pharmaceutical formulation comprising an anti-epidermal growth factor receptor (EGFR) antibody. The pharmaceutical formulation has low turbidity, without showing aggregation or particle formation, even under accelerated conditions, and exhibits good stability. Therefore, the pharmaceutical formulation can be effectively used for the treatment of disorders such as cancer.
-
5.发明授权
公开(公告)号：EP2483309B1
公开(公告)日：2016-08-17
申请号：EP09850100.0
申请日：2009-11-02
发明人： KIM, Se-Ho , CHANG, Ki Hwan , HONG, Kwang-Won , SHIN, Yong-Won , KIM, Min-Soo , LEE, Hae-Won , SHIN, Yong Nam , RYOO, Kyung Hwan , SEO, Dong Hyuck , WON, Jong-Hwa , HUR, Min-Kyu
IPC分类号： C07K16/28
CPC分类号： C07K16/2863 , C07K2317/565
-
6.发明授权COMPOSITION AND FORMULATION COMPRISING RECOMBINANT HUMAN IDURONATE-2-SULFATASE AND PREPARATION METHOD THEREOF 有权组成及配方与重组人用于生产艾杜糖醛酸-2-硫酸和过程
公开(公告)号：EP2723369B1
公开(公告)日：2016-04-13
申请号：EP12803297.6
申请日：2012-06-15
发明人： JIN, Thong-Gyu , CHUNG, Yo Kyung , PAIK, Sang Hoon , PARK, Yoo Chang , SEO, Jinwook , CHOI, Yong Woon , SON, Jong Mun , KIM, Yong-Chul
CPC分类号： C12N9/16 , A61K38/465 , C12Y301/06013
-
7.发明公开
公开(公告)号：EP2483309A1
公开(公告)日：2012-08-08
申请号：EP09850100.0
申请日：2009-11-02
发明人： KIM, Se-Ho , CHANG, Ki Hwan , HONG, Kwang-Won , SHIN, Yong-Won , KIM, Min-Soo , LEE, Hae-Won , SHIN, Yong Nam , RYOO, Kyung Hwan , SEO, Dong Hyuck
IPC分类号： C07K16/28
CPC分类号： C07K16/2863 , C07K2317/565
摘要： Provided are antibodies specifically binding to the epidermal growth factor receptor (EGFR) which are effective for the treatment of EGFR-mediated cancers.
-
8.发明授权ARGININE-RICH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PEPTIDES THAT INHIBIT GROWTH AND METASTASIS OF HUMAN TUMOR CELLS BY BLOCKING ANGIOGENESIS 有权富含精氨酸抗血管内皮细胞生长因子肽，其生长和转移人肿瘤细胞BY阻断血管生成INHIBIT
公开(公告)号：EP1162991B1
公开(公告)日：2006-03-01
申请号：EP99960007.5
申请日：1999-12-21
摘要： Disclosed are novel peptides inhibitory of the activity of vascular endothelial growth factor (VEGF) and their use in the treatment of angiogenesis-related diseases, including cancer. A combinatorial library of peptides consisting of six amino acid residues were chemically synthesized and, from the library, specific amino acid residues for each amino acid position were screened by comparing their inhibitory activity against VEGF binding to the cell surface receptor. The novel peptide sequences thus obtained bind to VEGF and block the binding of VEGF to its receptors present on the surface of vascular endothelial cells, thereby inhibiting the hormonal activity of VEGF. The peptides inhibit the angiogenesis induced by VEGF and human cancer cells. Also, the peptides inhibit growth and metastasis of human cancer cells transplanted to mice. Thus, the peptides can be used to treat angiogenesis-related diseases, including cancer, diabetic retinopathy, rheumatoid arthritis, etc.
-
9.发明授权HUMANIZED ANTIBODY SPECIFIC FOR SURFACE ANTIGEN PRE-S1 OF HBV AND PREPARATION METHOD THEREOF 有权专门为乙肝表面抗原前S1及其制备人源化抗体
公开(公告)号：EP1131358B1
公开(公告)日：2004-12-22
申请号：EP99972646.6
申请日：1999-11-19
发明人： HONG, Hyo, Jeong , RYU, Chun, Jeih , HUR, Hyangsuk
IPC分类号： C07K16/28 , C12N15/13 , C12N15/63 , A61K39/395
CPC分类号： C07K16/082 , C07K2317/24 , C07K2317/56 , C07K2317/92
-
10.发明公开HUMANIZED ANTIBODY SPECIFIC FOR SURFACE ANTIGEN PRE-S1 OF HBV AND PREPARATION METHOD THEREOF 有权专门为乙肝表面抗原前S1及其制备人源化抗体
公开(公告)号：EP1131358A1
公开(公告)日：2001-09-12
申请号：EP99972646.6
申请日：1999-11-19
发明人： HONG, Hyo, Jeong , RYU, Chun, Jeih , HUR, Hyangsuk
IPC分类号： C07K16/28 , C12N15/13 , C12N15/63 , A61K39/395
CPC分类号： C07K16/082 , C07K2317/24 , C07K2317/56 , C07K2317/92
摘要： The present invention relates to humanized antibodies specific for HBV surface antigen pre-S1, which show binding affinity similar to mouse monoclonal antibody and which show remarkably reduced immunogenicity since they have less mouse-derived amino acid residues. Thus, the humanized antibodies of the present invention may be useful for the prevention of HBV infection and for the treatment of hepatitis B.
-
-
-
-
-
-
-
-
-
搜索结果
500 条记录 (耗时 0.019 秒)
